Publication
Elucidating distinct roles for NF1 in melanomagenesis.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerCutaneous Melanomacivic_curation1.00
- drugMirdametinibcivic_curation1.00
- drugSirolimuscivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneNF1civic_curation1.00
- variantNF1 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23171796
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NF1 Mutation2 | ||||||||
| Mirdametinib + SirolimusCombination | Cutaneous MelanomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1469Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more … (full text at CIViC) PMID 23171796 · Maertens et al., 2013 · Open in CIViC | civic |
| Vemurafenib | Cutaneous MelanomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID1468Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In … (full text at CIViC) PMID 23171796 · Maertens et al., 2013 · Open in CIViC | civic |
| NF1 Loss1 | ||||||||
| Dabrafenib | Melanoma | Predictive | D | Supports Resistance | 3 | submitted | EID1957Taken together with preclinical studies in the mouse model and genetic studies in human melanoma cell lines, these observations further support the hypothesis that NF1/neurofibromin suppression may pl… (full text at CIViC) PMID 23171796 · Maertens et al., 2013 · Open in CIViC | civic |